Join Metabolon and DNA Genotek experts for a live webinar as we reveal new tools that demystify the microbiome and its impact on host health. Register today!
The outcome of a high-stakes advisory panel Tuesday could open the door for millions of kids to receive Pfizer's coronavirus vaccine. Here's what we know.
The company hopes a "streamlined" sales force can turn around a drug launch that's failed to meet expectations amid tough competition from rival medicines.
Sales of Aduhelm during the third quarter totaled only $300,000, falling well below expectations amid controversy over its approval and physician reluctance to prescribe it.
A relatively new class of parenteral drug products on the market — therapeutic oligonucleotides — poses new challenges to the pharmaceutical manufacturing process.
A closely watched competitor to Merck's molnupiravir failed a Phase 2 study, prompting its makers to change their strategy in a move that could delay an answer on the drug's efficacy until late next year.
Though the study's primary goal was missed, Biogen claimed there were some signs its drug, tofersen, could slow the disease's progression. The company is now engaging with regulators to discuss tofersen's future.
The biotech won EU approval for two gene therapies, Zynteglo and Syksona, both of which it will pull from market after difficulties negotiating reimbursement.
BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships.
BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries.
This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255 23rd Street NW, Suite 550, Washington, DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.
No comments:
Post a Comment